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2Abstract
Objectives: To assess evaluative methodologies for comparative measurements of test
sensitivity in clinical mammographic screening trials of computer-aided detection (CAD)
technologies.
Materials and Methods: This meta-analysis was performed by analytically reviewing
the relevant literature on the clinical application of computer-aided detection (CAD)
technologies as part of a breast cancer screening program based on x-ray mammography.
Each clinical study’s method for measuring the CAD system’s improvement in test
sensitivity is examined in this meta-analysis. The impact of the chosen sensitivity
measurement on the study’s conclusions are analyzed.
Results: This meta-analysis demonstrates that some studies have inappropriately
compared sensitivity measurements between control groups and CAD enabled groups.
The inappropriate comparison of control groups and CAD enabled groups can lead to an
underestimation of the benefits of the clinical application of computer-aided detection
technologies.
Conclusions: The potential for the sensitivity measurement issues raised in this meta-
analysis to alter the conclusions of multiple existing large clinical studies is discussed.
Two large scale studies are substantially affected by the analysis provided in this study
and this meta-analysis demonstrates that computer-aided detection systems are
successfully assisting in the breast cancer screening process.
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studies, sensitivity.
4Introduction
Evidence suggests that the early detection of breast cancer through periodic
mammographic screening reduces the mortality associated with the disease [1, 2].
Computer-aided detection (CAD) systems have the potential to improve the breast cancer
screening process by marking suspicious tissues as potentially malignant on x-ray
mammograms, thus minimizing the likelihood of a cancer being missed by the
interpreting radiologist. CAD systems mark suspect cancerous tissues but also incorrectly
mark non-malignant tissues, thus although a CAD system may provide improvements in
the rate of detection of cancers and may improve the sensitivity of the screening process,
it may also cause false positives, leading to higher recall rates and unnecessary biopsies.
This article is focused on how clinical CAD studies measure a test’s sensitivity and how a
clinical study’s methodology can affect the study’s conclusions.
Research has been ongoing in the design and development of CAD systems to help
radiologists with the breast cancer screening process. The research and development of a
CAD system typically incorporates rounds of lab based evaluation, comparing the CAD
marked results with ground truth data. Once a CAD system has performed successfully in
earlier evaluative studies, the technology may reach the stage whereby it is evaluated
clinically on ongoing examinations that are being actively relied upon for the detection of
breast cancer. Typically, testing a CAD system on an active screening population is
performed with commercially available CAD technology. This meta-analysis focuses on
those CAD studies that were performed in a clinical setting. The studies included in the
5detailed analysis herein tested CAD systems in a prospective manner, by measuring the
CAD system’s performance on a set of mammographic examinations actively being used
to screen for breast cancer. Thus this meta-analysis exclusively analyzes those CAD
studies that have reached a relatively advanced state of clinical use.
In the course of a typical clinical CAD study, numerous performance metrics are
computed to assist with the process of evaluating the performance of the CAD
technology being tested (cancer detection rates, test sensitivity, recall rates, biopsy rates,
size and stage of detected cancers, test specificity, etc.). Variations exist in the way a
clinical study calculates its performance metrics and in particular, variations exist in how
those performance metrics are compared. This meta-analysis reviews variations in the
methods for measuring a test’s sensitivity in clinical CAD studies for breast cancer
detection from x-ray mammography and discusses the potential negative effects of
relying on a direct comparison of the sensitivity measurements used.
Clinical studies of the effects of CAD technology can be divided into two groups:
matched studies and longitudinal studies. In matched studies a radiologist will analyze a
mammogram and are then exposed to the results of the CAD technology which may
change their diagnosis. Since the imaging examinations are carefully matched and
analyzed first without and then with CAD, one can be confident that comparing the
6measured test sensitivity before and after CAD based screening appropriately reflects the
potential performance improvements achieved by the CAD system.
True sensitivities are not computed in these studies as the number of missed cancers is an
inherent unknown. Instead, it should be recognized that a sensitivity measurement is
relative and as such great care needs to be taken in order to ensure that two measured
sensitivity values are indeed appropriate for direct comparison between the control group
and the CAD enabled group. Potential problems with a clinical CAD study can occur
when the test sensitivities of two groups are compared inappropriately (ie. between CAD
enabled screening and screening with no CAD technology).
When a CAD system’s relative improvement over non-CAD enabled screening is
measured in longitudinal studies it is typically assessed by comparing the test metrics
between two large groups (CAD enabled and non-CAD enabled). These groups are not
matched, and as such problems can occur when we compare large population groups with
a measurement like the test’s sensitivity. If a CAD system gets introduced and in its first
year of operation increases the yield of cancers detected (ie. a real increase in the cancer
detection rate), then it is normal to expect to see an associated increase in the test’s
measured sensitivity, however this is not necessarily the case. When the breast imaging
mammograms are not matched in the study design, then the sensitivity of the control
group can be inadvertently inflated relative to the CAD-enabled group. This can occur
7because missed some cancerous exams in the control group that would have been caught
had CAD been used get counted as true negatives when they are in fact false negatives.
This makes comparing sensitivity values between the control group and the CAD enabled
group potentially misleading. When the control group counts false negatives as true
negatives, its sensitivity is artificially inflated relative to the experimental CAD enabled
group. This effect is discussed in more detail in the Discussion.
8Materials and Methods
Measuring Sensitivity
A test’s sensitivity is typically assessed as the amount of disease detected relative to the
total cases of known disease in the population. The typical definition for a test’s
sensitivity is provided in equation 1.
FNTP
TPySensitivit

 (1)
Where,TP are the true positives: the malignancies caught by the given screening method
FN are the false negatives: cases of known missed cancers
This meta-analysis involved a detailed literature search in order to identify large scale
clinical studies looking at the benefits of computer-aided detection enabled breast cancer
screening. Each large scale clinical CAD study was analyzed based on the methodology
used to compare CAD enabled screening with alternative screening methodologies. In
this meta-analysis, each large scale clinical study’s test evaluation methodology was
analyzed and the potential impact of comparing test sensitivities inappropriately is
discussed.
9Results
The clinical assessment of computer-aided detection technologies for x-ray
mammographic breast cancer screening has yielded numerous matched studies [3-14].
Such studies typically incorporate an initial non-CAD enabled reading by a radiologist,
followed by reinterpretation with the benefit of the analyzed results produced by the
CAD system being tested. These studies are not affected by the arguments made in this
meta-analysis as the authors’ study design carefully examines individual screening
examinations with and without the use of CAD technology. Thus cases where the CAD
system detects an otherwise missed tumour are clearly recorded and included in the
analysis. Potential benefits of CAD enabled screening are clearly analyzed in these types
of studies.
Non-matched population based analyses of CAD technologies account for 7 studies
found in the literature [15-21]. Each study is summarized in Table 1, along with the
potential extent to which this meta-analysis may contribute to reinterpreting the study’s
results.
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Table 1: CAD studies for x-ray mammography – potential effect of this meta-analysis
Study Reported Sensitivity
Improvement
Impact of this Meta-
analysis
Gur et al.15 (JNCI, 2004) None – other metrics
used
none
Cupples et al.16 (AJR, 2005) None – other metrics
used
none
Fenton et al.17 (NEJM, 2007) 3.6% over pre-CAD Substantial
Gromet18 (AJR, 2008) 9% over single reader Very small
Gilbert et al.19 (NEJM, 2008) Equal to double reader Very small
James et al.20 (Radiology, 2010) Equal to double reader Very small
Fenton et al.21 (JNCI, 2011) 1.4% over pre-CAD.
CAD had a lower
sensitivity compared
with non-CAD controls.
Substantial
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Discussion
Critical to evaluating a new screening technology is the correct accounting (true
positives, false negatives) of those cancers that could be caught by the new CAD-enabled
screening process. In a non-matched longitudinal population study, a misleading problem
can occur with respect to evaluating the quality of the CAD system. Consider those
malignant lesions that potentially can be caught by CAD but are not caught because they
are in the control group where CAD wasn’t implemented. Cases that can be caught by
CAD but are not caught by manual radiological analysis are the most critical cases for
accurately assessing the sensitivity improvement of CAD-enabled screening. Non-
matched studies that compare test sensitivities between control groups and CAD enabled
groups can potentially be misleading due to an assumption of a lack of cancers in the
control group’s negative screening findings.
In a typical non-matched longitudinal population study, malignant lesions presenting on
mammography that are missed by a radiologist but able to be caught by the CAD system
and would be caught by future rounds of regular screening are counted as true negatives
(ie. they are diagnosed as non-cancerous and then erroneously evaluated as correctly
diagnosed). These cases of missed cancers that could have been caught by CAD are
critical to assessing the CAD system’s performance improvement over standard
screening. Instead of being counted as true negatives, these cases should be counted as
false negatives (ie. an erroneous non-cancerous diagnosis). An increase in false negatives
contributes to lowering the measured test sensitivity (see equation 1). Comparing test
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sensitivities of a control group with a CAD enabled group in a non-matched study can
result in an underestimation of the difference in test sensitivity between the CAD enabled
group and the control group. Thus comparing sensitivity measures between two
independent groups can imply a smaller sensitivity improvement than was actually
accomplished by the introduction of CAD technology because missed cancers in the
control group that were CAD detectable are regularly incorrectly counted as correctly
diagnosed non-cancers (true negatives) when they are actually incorrectly diagnosed
cancers (false negatives).
In preclinical CAD trials, the outlined comparative sensitivity problem is usually not an
issue as pre-clinical CAD evaluation does not tend to compare two pools of samples
separately. Instead individual exams are typically matched such that multiple screening
methods are tested on the exact same mammograms and directly compared. Thus a
typical lab-based evaluation of a CAD system does not suffer from the comparative
sensitivity problems discussed in this paper. The matched clinical studies investigating
the use of CAD [3-14] also do not appear to suffer from the problems with analyzing
results by comparing the sensitivity of two different screening methods. In these
situations we can be confident that any sensitivity measures produced are a reasonable
method by which to compare two screening methodologies.
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The longitudinal studies which compare separate populations, one with CAD and one
without CAD can lead to erroneous conclusions when analysis of screening technologies
is based on comparing sensitivities measured for each group. Two of the six longitudinal
CAD studies included in Table 1 in this paper’s results avoided the test sensitivity as an
evaluative metric and so are not affected by the comparative sensitivity issues presented
in this meta-analysis [15, 16]. Three additional longitudinal studies from Table 1 are
affected by this comparative sensitivity issue, however, those study also included dual
reading in the control group [18-20] which should help minimize the potential negative
effects described in this analysis. This is because in the control group, the second reader
often identifies extra malignancies that would have been caught by the CAD system,
which in turn prevented those cases from being miscounted as true negatives. Thus the
expected impact of this meta-analysis on Gromet’s study [18], Gilbert’s study [19] and
James’ study [20] is expected to be very small as indicated in Table 1.
Two of the six longitudinal CAD studies are potentially substantially affected by the
arguments raised in this analysis [17, 21]. Those two studies’ conclusions only
emphasized the existence of extremely minor benefits of CAD enabled screening. The
effect described in this meta-analysis is liable to have reduced the difference between the
measured sensitivities of the control groups relative to the CAD enabled groups because
the control groups’ sensitivities are not degraded for the missed cancers that would have
been caught by CAD had it been deployed in the control population. This may help
explain why the more recent study in the Journal of the National Cancer Institute [21]
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reported higher sensitivities in the non CAD-enabled control group relative to the CAD
enabled group – an initially surprising finding. This may also explain why only a very
small sensitivity improvement was reported when comparing the CAD enabled group
with the pre-CAD control group (1.4% improvement). It is interesting to note that
although both studies emphasized meager benefits from CAD technology [17, 21], the
earlier study in the New England Journal of Medicine [17] indicates that CAD screening
actually resulted in an increase in the rate of detection of ductal carcinoma in situ (DCIS)
by 34% and a decrease in the rate of detection of invasive cancers by 12%, indicating that
CAD use may have contributed to shifting the tumour yield towards earlier stage pre-
invasive cancers (which are known to have more favourable prognostic characteristics).
The later study of the two from the Journal of the National Cancer Institute [21] also
showed a statistically significant shift towards more DCIS yield in CAD-enabled
screening [22], indicating that contrary to the author’s conclusions, CAD has exhibited a
constructive role in the breast cancer screening process.
In order to help illustrate the problems with comparing measured sensitivities in
unmatched longitudinal trials, consider the simple example of a screening center which
annually catches 800 cancers with mammography. Furthermore, 200 patients screened at
that center are diagnosed with breast cancer annually, even though they had a negative
mammogram for a total of 1000 patients diagnosed with breast cancer annually. By the
methods used in the literature [17, 21], the center’s sensitivity will be 800/(800+200) =
80%. If we then add a CAD system that catches 100 extra tumours in its first round of
screening and those tumours would have otherwise been caught in a subsequent round of
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screening (CAD contributes to catching those tumours earlier), then the sensitivity (as
measured [17, 21]) would be 900/(900+200) = 81.8%. Direct comparison reveals just a
1.8% absolute increase in the test sensitivity even though the introduction of the CAD
system resulted in an increased yield of malignant tumours of 12.5% (100/800) in the
first year of operation.
If this hypothetical screening center had implemented CAD technology one year earlier,
then we would expect the CAD system to have yielded an additional 100 lesions in the
year it was introduced. The computed sensitivity for the control group prior to
implementation of CAD does not account for these missed malignancies that would have
been caught had CAD been implemented earlier. Instead those malignancies are missed
and erroneously counted as correct diagnoses of exams without malignancies. Consider
the control group in a situation where there are 100 missed cancers that could have been
caught by CAD and would eventually be caught by a future round of traditional non-
CAD based screening. The aforementioned testing methodologies [17, 21] would only
account for the normal 200 cases of cancer caught in spite of the implementation of
mammographic screening (screened women who present with cancer after a negative
mammogram). The control group’s sensitivity would be computed as
800/(800+200)=80%, when there are in fact 100 extra missed cancers that were not
accounted for and so a more accurate sensitivity for the control population would be
800/(800+300)=72.7%. Comparing this hypothetical control with a CAD enabled group
yielding an 81.8% sensitivity demonstrates a solid improvement in the test’s sensitivity.
Such a comparison is not made however, as these cancers are not accounted for in the
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computation of the test’s sensitivity [17, 21]. It should be noted that the above is just a
simple example, however, it clearly illustrates that it is possible for a real improvement in
cancer yield of 12.5% (100/800) to result in as little as a 1.8% improvement in sensitivity
when relying on problematic methods for comparing sensitivity measurements [17, 21].
The earlier study in the New England Journal of Medicine [17] looked exclusively at the
performance of a particular CAD technology (ImageChecker, R2 Technology) and
averaged its performance across a variety of centers. The more recent study from the
Journal of the National Cancer Institute [21] averages together 25 CAD screening
centers. It was not reported whether all of these centers employed the same commercial
CAD technologies. It is expected that different CAD technologies from different vendors
will produce different benefits. Furthermore, Dr. Nishikawa and Lorenzo Pesce’s analysis
demonstrates that different CAD systems for mammographic breast cancer detection can
range in disease detection rate improvements from 5 to 20% in cross-sectional trials [23].
Considerable variation also exists between individual radiologists and between different
screening centers.
A safer method for evaluating a disease screening technology in a longitudinal clinical
context would be to look at the increase in the disease detection rate during the first
year/round of screening with a new detection technology. Measuring the disease
detection rate beyond this period in a longitudinal trial can lead to misleading conclusions
because of the lowered prevalence of disease in the population after introduction of a new
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more sensitive screening method [23-24]. Additionally, examining the detected tumours’
size and stage are appropriate measures for the evaluation of a screening technology.
Sensitivities are relative measurements, when comparing two sensitivities great care must
be taken to ensure that the comparison is appropriate so as not to result in misleading
conclusions. Of the many large scale clinical studies included in this meta-analysis, the
two that are most affected by this paper [17, 21] also demonstrate some of the least
benefits from computer-aided detection enabled mammographic screening, indicating
that computer-aided detection systems are in fact assisting in mammographic breast
cancer screening. The results of this meta-analysis have been published in the journal
Radiology [25].
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